Pro-Regenerative Biomaterials for Women's Health

Karen L. Christman, PhD

Shu Chien-Gene Lay Department of Bioengineering Sanford Consortium for Regenerative Medicine, UC San Diego



Disclosures


ventrixbio

- Co-founder
- Consultant
- Board Member
- Hold Equity



- Co-founder
- Consultant
- Board Member
- Hold Equity


Pro-Regenerative Biomaterial Scaffolds




- Synthetic or naturally derived biomaterials
- Promote pro-remodeling immune response (M2, Th2) to drive regeneration
- More cost effective than cells
- No living product (less storage, shipping, and preparation concerns)
- Potential for sterilization
- More reproducible
- Some applications/materials can be regulated as devices




MAP Scaffolds: Microporous Annealed Particles








ECM Hydrogels




ECM Hydrogels for Cardiovascular Disease

Myocardial Infarction/ Ischemic Heart Failure




Singelyn et al., *JACC*, *2012*; Seif-Naraghi et al., *Science Translational Medicine*, 2013; Wassenaar et al., *JACC*, 2016; Wang et al., *Acta Biomaterialia*, 2022; Traverse et al., JACC:BTS, 2019

Hypoplastic Left Heart Syndrome



Hunter, et al., JACC BTS, 2024

Peripheral Artery Disease



Ungerleider, Johnson et al, JACC: BTS, 2016



Pelvic Floor Disorders



Pelvic Organ Prolapse




Urinary Incontinence



Fecal Incontinence


- Presently
 ~25% of U.S. Women
- Negative Impact on Quality of Life
- Large Associated Costs
- Increasing Demand for Care


Vaginal Delivery: Leading Risk Factor for Pelvic Floor Injury



ECM Hydrogels for Women's Health


Pelvic Floor Muscle Injury






- Modulation of immune response
- Upregulation of myogenesis pathway
- Downregulation of genes related with ECM remodeling


Genitourinary Syndrome of Menopause







Challenges for Translating Pro-Regenerative Biomaterials for Women's Health



- Don't know the exact pathology and disease progression at the molecular, cellular, and tissue level in women
- Don't know the optimal time to deliver a regenerative therapy
- Lack of precedent
 - Unclear preclinical path for IND for many indications (what animal models will be required?)
 - Best outcome measures for trials not defined
 - Which patients will benefit most?
- Raising funds with new/different technologies can be challenging

Acknowledgements

Christman Lab

Rebecca Braden, MS Colin Luo Emma Zelus, PhD Maria Karkanitsa Alex Chen Bianca Peña Michael Nguyen, PhD Quincy Lyons **Emily Gardner** Maria Samaritano

Collaborators

Anthony DeMaria, MD Ryan Reeves, MD Nabil Dib, MD Nathan Gianneschi, PhD Michael Davis, PhD Michael Madani. MD Shami Mahmud, MD Kirk Hansen, PhD Mark Hepokoski, MD Sylvia Evans, PhD Marianna Alperin, MD Francisco Contijoch, PhD Pedro Cabrales, PhD Ester Kwon, PhD Lola Eniola-Adefeso, PhD Kevin King, MD PhD

Former Lab Members

Jennifer Singelyn, PhD

Jessica DeQuach, PhD Kevin Chung, MS Priya Sundaramurthy, MS Kristina Javor, MS Aubrey Smith, MS Stephen Lin, MS Airong Song, PhD Pam Schup-Magoffin Aboli Rane, PhD Sonya Sonnenberg, PhD Adam Young, PhD Nikhil Rao, PhD Greg Grover, PhD Sophia Suarez, PhD Todd Johnson, PhD Heinz Strässle, MS Mary Nguyen, PhD Jean Wassenaar, PhD Eva van Ingen, MS Soraya Aouad, MS Hillary Lam, MS Lea de Maddalena Andrea Luthi, PhD Vera Pieters Austin Burdick, MS Masaki Fujita, MS Jessica Ungerleider, PhD Gina Policastro, PhD Melissa Hernandez, PhD Roberto Gaetani, PhD Ray Wang, PhD Taka Kato Marty Spang, PhD Ryan Middleton, PhD

Miranda Diaz, PhD Holly Sullivan, PhD Pamela Duran, PhD Jervaughn Hunter, PhD Josh Mesfin, PhD Danna Du, MS

Clinical Investigators

Jay Traverse, MD Tim Henry, MD Amit Patel, MD Nabil Dib, MD Carl Pepine, MD Gary Schaer, MD

Funding











AWARD

NIH DIRECTOR'S













